| scholarly article | Q13442814 |
| P50 | author | Renato Morona | Q67710103 |
| P2093 | author name string | Paton AW | |
| Paton JC | |||
| P2860 | cites work | Polymerase chain reaction amplification, cloning and sequencing of variant Escherichia coli Shiga-like toxin type II operons | Q48111671 |
| Effect of lipopolysaccharide core synthesis mutations on the production of Vibrio cholerae O-antigen in Escherichia coli K-12 | Q54693159 | ||
| Globotetraosylceramide is recognized by the pig edema disease toxin | Q69517260 | ||
| Heterogeneity of the amino-acid sequences of Escherichia coli Shiga-like toxin type-I operons | Q72613120 | ||
| A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans | Q73505003 | ||
| Diarrheagenic Escherichia coli | Q24533466 | ||
| Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections | Q24550740 | ||
| Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors | Q26778475 | ||
| Molecular characterization of the locus encoding biosynthesis of the lipopolysaccharide O antigen of Escherichia coli serotype O113 | Q30798461 | ||
| Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine | Q36215407 | ||
| The pathogenesis of edema disease in pigs. A review | Q36303500 | ||
| Variation of gonococcal lipooligosaccharide structure is due to alterations in poly-G tracts in lgt genes encoding glycosyl transferases | Q36366145 | ||
| Infection by verocytotoxin-producing Escherichia coli | Q36634680 | ||
| Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants | Q36977977 | ||
| Shiga and Shiga-like toxins | Q37063416 | ||
| Polyisobutylmethacrylate modifies glycolipid binding specificity of verotoxin 1 in thin-layer chromatogram overlay procedures | Q38329511 | ||
| The assembly system for the outer core portion of R1- and R4-type lipopolysaccharides of Escherichia coli. The R1 core-specific beta-glucosyltransferase provides a novel attachment site for O-polysaccharides. | Q38331959 | ||
| Construction of vectors with the p15a replicon, kanamycin resistance, inducible lacZ alpha and pUC18 or pUC19 multiple cloning sites | Q40523796 | ||
| Role of verotoxin receptors in pathogenesis | Q41052833 | ||
| The gene cluster directing O-antigen biosynthesis in Yersinia enterocolitica serotype 0:8: identification of the genes for mannose and galactose biosynthesis and the gene for the O-antigen polymerase | Q41491781 | ||
| Genetic locus for the biosynthesis of the variable portion of Neisseria gonorrhoeae lipooligosaccharide | Q42594524 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1967-1970 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Infection and Immunity | Q6029193 |
| P1476 | title | Neutralization of Shiga toxins Stx1, Stx2c, and Stx2e by recombinant bacteria expressing mimics of globotriose and globotetraose | |
| P478 | volume | 69 |
| Q30940276 | A new family of potent AB(5) cytotoxins produced by Shiga toxigenic Escherichia coli |
| Q37260988 | Adherence, anti-adherence, and oligosaccharides preventing pathogens from sticking to the host |
| Q28087714 | Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype |
| Q34518407 | Bioengineered bugs expressing oligosaccharide receptor mimics: toxin-binding probiotics for treatment and prevention of enteric infections |
| Q33883354 | Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells |
| Q36389297 | Designer probiotics for prevention of enteric infections. |
| Q26795388 | Designer probiotics: Development and applications in gastrointestinal health |
| Q34999780 | Development of monoclonal antibodies and immunoassays for sensitive and specific detection of Shiga toxin Stx2f |
| Q44724601 | Differential carbohydrate epitope recognition of globotriaosyl ceramide by verotoxins and a monoclonal antibody |
| Q38024274 | Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature |
| Q38287346 | Functional characterization of Gne (UDP-N-acetylglucosamine-4-epimerase), Wzz (chain length determinant), and Wzy (O-antigen polymerase) of Yersinia enterocolitica serotype O:8 |
| Q39648887 | Functional expression of enterobacterial O-polysaccharide biosynthesis enzymes in Bacillus subtilis. |
| Q35542652 | Genetically engineered probiotics |
| Q38086151 | Glycans-by-design: engineering bacteria for the biosynthesis of complex glycans and glycoconjugates |
| Q33385809 | Hemolytic uremic syndrome: pathogenesis and update of interventions |
| Q42284960 | Lactobacillus plantarum isolated from kefir protects vero cells from cytotoxicity by type-II shiga toxin from Escherichia coli O157:H7. |
| Q36891324 | New Monoclonal Antibodies against a Novel Subtype of Shiga Toxin 1 Produced by Enterobacter cloacae and Their Use in Analysis of Human Serum |
| Q35698625 | New Stx2e Monoclonal Antibodies for Immunological Detection and Distinction of Stx2 Subtypes |
| Q35220308 | Prebiotic galactooligosaccharides reduce adherence of enteropathogenic Escherichia coli to tissue culture cells |
| Q37111223 | Probiotics and gastrointestinal infections |
| Q36402193 | Probiotics and prebiotics in human health. |
| Q28488900 | Purification and characterization of Shiga toxin 2f, an immunologically unrelated subtype of Shiga toxin 2 |
| Q28258559 | Rational design of improved pharmabiotics |
| Q33395662 | Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli |
| Q34739913 | Shiga toxin subtypes display dramatic differences in potency |
| Q42591654 | Strategies to avoid Shiga toxin effects |
| Q92153341 | Structural and Functional Characterization of Stx2k, a New Subtype of Shiga Toxin 2 |
| Q35012815 | Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants |
| Q36901746 | Targeting ricin to the ribosome |
| Q39679036 | The O-antigen gene cluster of Escherichia coli O55:H7 and identification of a new UDP-GlcNAc C4 epimerase gene |
| Q33415691 | Therapeutic use of a receptor mimic probiotic reduces intestinal Shiga toxin levels in a piglet model of hemolytic uremic syndrome |
| Q33376138 | Treatment and prevention of enterohemorrhagic Escherichia coli infection and hemolytic uremic syndrome |
| Q33399468 | Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS). |
| Q91975349 | Verotoxin Receptor-Based Pathology and Therapies |
Search more.